SCHEDULE: Vanguard Group Reports 0% Stake in CG Oncology

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in CG Oncology Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership of Common Stock in CG Oncology Inc.
• As of March 13, 2026, The Vanguard Group reports 0.00 shares beneficially owned, representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions will report beneficial ownership separately, and The Vanguard Group, Inc. no longer has beneficial ownership over these securities.
• The realignment ensures that these subsidiaries continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development for CG Oncology, as the reduction in Vanguard's reported stake is due to internal restructuring rather than a negative view on the company, and Vanguard-affiliated entities may still hold shares.

Positives

• The change in beneficial ownership is due to an internal corporate realignment at Vanguard, not a divestment based on CG Oncology's performance.
• Vanguard's subsidiaries will continue to pursue the same investment strategies, implying continued potential investment in CG Oncology by Vanguard-affiliated entities.

Negatives

• The Vanguard Group, as the primary reporting entity, no longer directly holds beneficial ownership in CG Oncology Inc.

Risks

• While the filing states the change is due to internal realignment, a significant reduction in reported beneficial ownership by a major institutional investor like Vanguard could be misinterpreted by some market participants as a negative signal, potentially impacting investor sentiment.

Management Comments

• The Vanguard Group, Inc. went through an internal realignment on January 12, 2026.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that internal realignments within large asset managers like Vanguard are not uncommon and often reflect organizational changes rather than a specific investment thesis change regarding the underlying company. This disaggregated reporting aligns with SEC guidance for complex organizational structures.

Stakeholder Impact

• Shareholders: May initially perceive a large institutional investor reducing its stake as negative, but the explanation of internal realignment should mitigate concerns. The actual underlying holdings by Vanguard-affiliated entities may not have changed significantly.

Key Dates

Recommendation

The filing indicates a technical change in reporting beneficial ownership by The Vanguard Group due to an internal realignment, rather than a strategic divestment from CG Oncology Inc. While the headline might suggest a reduction in institutional interest, the underlying investment strategies of Vanguard's subsidiaries remain unchanged. Therefore, this filing alone does not provide a strong basis for a 'buy' or 'sell' recommendation, warranting a 'hold' as investors await further company-specific news from CG Oncology.

Keywords

CG Oncology Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Corporate Realignment